EGFR and meningioma: Based on this background, two of the low molecular weight anti-EGFR inhibitors, gefitinib and erlotinib, were introduced in phase II clinical trials in patients with recurrent meningioma (North American Brain Tumor Consortium Trials 00–01 and 01–03).